EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Promising New Anti‐ TIGIT Agents: Stealthy Allies in Cancer Immunotherapy

Gatadi Srikanth iD, Durga Prasad Beda, Ashish Ranjan Dwivedi, Nandan Kumar Duddukuri, Srinivas Nanduri, Jitendra Patel iD

Clinical and Translational Science · 2025-04 · 18 (4)

DOI: 10.1111/cts.70212 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 22.04.2025. Verfasst von Gatadi Srikanth und 5 weiteren Autor:innen. Beteiligte Einrichtung: GITAM School of Pharmacy, GITAM (Deemed to Be University), Hyderabad, India. Hauptthemen laut MEDLINE: Neoplasms, Receptors, Immunologic, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: SEED, Science for Equity, Empowerment and Development Division.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TIGIT (T cell immunoreceptor with immunoglobulin and tyrosine‐based inhibitory motif (ITIM) domain), Vstm3, and VSIG9, are newly recognized immunological checkpoints. They are prominently expressed on CD4+ and CD8+ T cells, tumor‐infiltrating lymphocytes (TILs), natural killer (NK) cells, and regulatory T cells (Tregs). The TIGIT (TIGIT) protein is crucial for immune modulation since it diminishes NK cell populations and hinders T cell activity in cancer patients and experimental models. CD155, the principal ligand of TIGIT in humans, has been recognized as a pivotal target for immunotherapy owing to its interaction with TIGIT. CD155 is linked to the efficacy of anti‐programmed cell death protein 1 (PD‐1) therapy, even without TIGIT expression, underscoring its importance in immune checkpoint suppression. Anti‐TIGIT medicines, either independently or in conjunction with anti‐PD‐1 treatments, have demonstrated potential in augmenting immune responses to malignancies. This review examines the structural and functional characteristics of the TIGIT protein, new developments in anti‐TIGIT drugs, and their prospective use in cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsReceptors, ImmunologicImmunotherapyImmune Checkpoint InhibitorsHumansAnimalsReceptors, Virus

Stichwörter der Autor:innen

PD‐1TIGITcancerimmunotherapyresistance

Substanzen

TIGIT protein, humanReceptors, ImmunologicImmune Checkpoint InhibitorsReceptors, Viruspoliovirus receptor

Autor:innen und Institutionen

  • GITAM School of Pharmacy, GITAM (Deemed to Be University), Hyderabad, India.
  • Chemistry Division, Innatura Scientific Pvt. Ltd., Hyderabad, Telangana, India.
  • Department of Chemical Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
  • Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education, (Deemed to Be University), Wardha, Maharashtra, India.

ORCID-Profile: Gatadi Srikanth, Jitendra Patel

Förderung

  • SEED
  • Science for Equity, Empowerment and Development Division

Zitieren

APA

Srikanth, G., Beda, D. P., Dwivedi, A. R., Duddukuri, N. K., Nanduri, S., & Patel, J. (2025). Promising New Anti‐ TIGIT Agents: Stealthy Allies in Cancer Immunotherapy. Clinical and Translational Science, 18(4). https://doi.org/10.1111/cts.70212

Vancouver

Srikanth G, Beda DP, Dwivedi AR, Duddukuri NK, Nanduri S, Patel J. Promising New Anti‐ TIGIT Agents: Stealthy Allies in Cancer Immunotherapy. Clinical and Translational Science. 2025;18(4). doi:10.1111/cts.70212

BibTeX
@article{Srikanth2025,
  author = {Srikanth, Gatadi and Beda, Durga Prasad and Dwivedi, Ashish Ranjan and Duddukuri, Nandan Kumar and Nanduri, Srinivas and Patel, Jitendra},
  title = {Promising New Anti‐ TIGIT Agents: Stealthy Allies in Cancer Immunotherapy},
  journal = {Clinical and Translational Science},
  year = {2025},
  volume = {18},
  number = {4},
  doi = {10.1111/cts.70212}
}
Kostenlos starten →